Cytokinetics Total Current Liabilities from 2010 to 2025
| CYTK Stock | USD 42.99 0.64 1.47% |
Total Current Liabilities | First Reported 2002-12-31 | Previous Quarter 109.8 M | Current Value 179.7 M | Quarterly Volatility 29.9 M |
Check Cytokinetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytokinetics' main balance sheet or income statement drivers, such as Interest Expense of 90.8 M, Other Operating Expenses of 582.5 M or Research Development of 356.4 M, as well as many indicators such as Price To Sales Ratio of 299, Dividend Yield of 0.0 or Days Sales Outstanding of 299. Cytokinetics financial statements analysis is a perfect complement when working with Cytokinetics Valuation or Volatility modules.
Cytokinetics | Total Current Liabilities |
Latest Cytokinetics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Cytokinetics over the last few years. Total Current Liabilities is an item on Cytokinetics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cytokinetics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Cytokinetics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytokinetics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Cytokinetics Total Current Liabilities Regression Statistics
| Arithmetic Mean | 54,658,106 | |
| Geometric Mean | 33,077,405 | |
| Coefficient Of Variation | 105.28 | |
| Mean Deviation | 44,274,521 | |
| Median | 31,649,000 | |
| Standard Deviation | 57,543,447 | |
| Sample Variance | 3311.2T | |
| Range | 184.1M | |
| R-Value | 0.83 | |
| Mean Square Error | 1080.1T | |
| R-Squared | 0.70 | |
| Significance | 0.000059 | |
| Slope | 10,080,238 | |
| Total Sum of Squares | 49668.7T |
Cytokinetics Total Current Liabilities History
About Cytokinetics Financial Statements
Cytokinetics investors utilize fundamental indicators, such as Total Current Liabilities, to predict how Cytokinetics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 179.7 M | 188.7 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Cytokinetics Correlation against competitors. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.26) | Revenue Per Share | Quarterly Revenue Growth 9.124 | Return On Assets | Return On Equity |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.